

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PERJETA safely and effectively. See full prescribing information for PERJETA.

PERJETA® (pertuzumab) injection, for intravenous use
Initial U.S. Approval: 2012

WARNING: LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY

See full prescribing information for complete boxed warning.

- **Left Ventricular Dysfunction:** PERJETA can result in subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF. Evaluate cardiac function prior to and during treatment. Discontinue PERJETA treatment for a confirmed clinically significant decrease in left ventricular function. (2.2, 5.1, 6.1)
- **Embryo-fetal Toxicity:** Exposure to PERJETA can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception. (5.2, 8.1, 8.3)

RECENT MAJOR CHANGES

None

INDICATIONS AND USAGE

PERJETA is a HER2/neu receptor antagonist indicated for:

- Use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (1.1)
- Use in combination with trastuzumab and docetaxel as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on demonstration of an improvement in pathological complete response rate. No data are available demonstrating improvement in event-free survival or overall survival. (1.2, 2.1, 14.2)

Limitations of Use:

- The safety of PERJETA as part of a doxorubicin-containing regimen has not been established.
- The safety of PERJETA administered for greater than 6 cycles for early breast cancer has not been established.

DOSAGE AND ADMINISTRATION

- **For intravenous infusion only.** Do not administer as an intravenous push or bolus. (2.3)
- The initial PERJETA dose is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by 420 mg administered as a 30 to 60 minute intravenous infusion. (2.1)

- **MBC:** Administer PERJETA, trastuzumab, and docetaxel by intravenous infusion every 3 weeks. (2.1)
- **Neoadjuvant:** Administer PERJETA, trastuzumab, and docetaxel by intravenous infusion preoperatively every 3 weeks for 3 to 6 cycles. (2.1)

DOSAGE FORMS AND STRENGTHS

- 420 mg/14 mL single-use vial. (3)

CONTRAINDICATIONS

PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients. (4)

WARNINGS AND PRECAUTIONS

- **Left Ventricular Dysfunction:** Monitor LVEF and withhold dosing as appropriate. (5.1, 6.1)
- **Infusion-Related Reactions:** Monitor for signs and symptoms. If a significant infusion-associated reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies. (5.3)
- **Hypersensitivity Reactions/Anaphylaxis:** Monitor for signs and symptoms. If a severe hypersensitivity reaction/anaphylaxis occurs, discontinue the infusion immediately and administer appropriate medical therapies. (5.4)
- **HER2 testing:** Perform using FDA-approved tests by laboratories with demonstrated proficiency. (5.5)

ADVERSE REACTIONS

Metastatic Breast Cancer

- The most common adverse reactions (> 30%) with PERJETA in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy. (6.1)

Neoadjuvant Treatment of Breast Cancer

- The most common adverse reactions (> 30%) with PERJETA in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. (6.1)
- The most common adverse reactions (>30%) with PERJETA in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of FEC were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. (6.1)
- The most common adverse reactions (>30%) with PERJETA in combination with docetaxel, carboplatin, and trastuzumab (TCH) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

Females and Males of Reproductive Potential: Verify the pregnancy status of females prior to initiation of PERJETA. (8.3)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 05/2017

FULL PRESCRIBING INFORMATION: CONTENTS***WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY****1 INDICATIONS AND USAGE**

- 1.1 Metastatic Breast Cancer
- 1.2 Neoadjuvant Treatment of Breast Cancer

2 DOSAGE AND ADMINISTRATION

- 2.1 Recommended Doses and Schedules
- 2.2 Dose Modification
- 2.3 Preparation for Administration

3 DOSAGE FORMS AND STRENGTHS**4 CONTRAINDICATIONS****5 WARNINGS AND PRECAUTIONS**

- 5.1 Left Ventricular Dysfunction
- 5.2 Embryo-Fetal Toxicity
- 5.3 Infusion-Related Reactions
- 5.4 Hypersensitivity Reactions/Anaphylaxis
- 5.5 HER2 Testing

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Immunogenicity

7 DRUG INTERACTIONS**8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment

10 OVERDOSAGE**11 DESCRIPTION****12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics
- 12.6 Cardiac Electrophysiology

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Metastatic Breast Cancer
- 14.2 Neoadjuvant Treatment of Breast Cancer

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the Full Prescribing Information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY

- **Left Ventricular Dysfunction:** PERJETA can result in subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF. Evaluate cardiac function prior to and during treatment. Discontinue PERJETA treatment for a confirmed clinically significant decrease in left ventricular function. (2.2, 5.1, 6.1)
- **Embryo-fetal Toxicity:** Exposure to PERJETA can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception. (5.2, 8.1, 8.3)

1 INDICATIONS AND USAGE

1.1 Metastatic Breast Cancer (MBC)

PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

1.2 Neoadjuvant Treatment of Breast Cancer

PERJETA is indicated for use in combination with trastuzumab and docetaxel for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on demonstration of an improvement in pathological complete response rate. No data are available demonstrating improvement in event-free survival or overall survival [see *Clinical Studies (14.2) and Dosage and Administration (2.1)*].

Limitations of Use:

- The safety of PERJETA as part of a doxorubicin-containing regimen has not been established.
- The safety of PERJETA administered for greater than 6 cycles for early breast cancer has not been established.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Doses and Schedules

The initial dose of PERJETA is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.

When administered with PERJETA, the recommended initial dose of trastuzumab is 8 mg/kg administered as a 90-minute intravenous infusion, followed every 3 weeks by a dose of 6 mg/kg administered as an intravenous infusion over 30 to 90 minutes.

PERJETA, trastuzumab, and docetaxel should be administered sequentially. PERJETA and trastuzumab can be given in any order. Docetaxel should be administered after PERJETA and trastuzumab. An observation period of 30 to 60 minutes is recommended after each PERJETA infusion and before commencement of any subsequent infusion of trastuzumab or docetaxel [see *Warnings and Precautions (5.3)*].

Metastatic Breast Cancer (MBC)

When administered with PERJETA, the recommended initial dose of docetaxel is 75 mg/m² administered as an intravenous infusion. The dose may be escalated to 100 mg/m² administered every 3 weeks if the initial dose is well tolerated.

Neoadjuvant Treatment of Breast Cancer

PERJETA should be administered every 3 weeks for 3 to 6 cycles as part of one of the following treatment regimens for early breast cancer [see *Clinical Studies (14.2)*]:

- Four preoperative cycles of PERJETA in combination with trastuzumab and docetaxel followed by 3 postoperative cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) as given in Study 2
- Three preoperative cycles of FEC alone followed by 3 preoperative cycles of PERJETA in combination with docetaxel and trastuzumab as given in Study 3
- Six preoperative cycles of PERJETA in combination with docetaxel, carboplatin, and trastuzumab (TCH) (escalation of docetaxel above 75 mg/m² is not recommended) as given in Study 3

Following surgery, patients should continue to receive trastuzumab to complete 1 year of treatment. There is insufficient evidence to recommend continued use of PERJETA for greater than 6 cycles for early breast cancer. There is insufficient evidence to recommend concomitant administration of an anthracycline with PERJETA, and there are no safety data to support sequential use of doxorubicin with PERJETA.

2.2 Dose Modification

For delayed or missed doses, if the time between two sequential infusions is less than 6 weeks, the 420 mg dose of PERJETA should be administered. Do not wait until the next planned dose. If the time between two sequential infusions is 6 weeks or more, the initial dose of 840 mg PERJETA should be re-administered as a 60-minute intravenous infusion followed every 3 weeks thereafter by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.

PERJETA should be discontinued if trastuzumab treatment is discontinued.

Dose reductions are not recommended for PERJETA.

For docetaxel dose modifications, see relevant prescribing information.

Left Ventricular Ejection Fraction (LVEF):

Withhold PERJETA and trastuzumab dosing for at least 3 weeks for either:

- a drop in LVEF to less than 45% or
- LVEF of 45% to 49% with a 10% or greater absolute decrease below pretreatment values [see *Warnings and Precautions (5.1)*]

PERJETA may be resumed if the LVEF has recovered to greater than 49% or to 45% to 49% associated with less than a 10% absolute decrease below pretreatment values.

If after a repeat assessment within approximately 3 weeks, the LVEF has not improved, or has declined further, PERJETA and trastuzumab should be discontinued, unless the benefits for the individual patient are deemed to outweigh the risks [see *Warnings and Precautions (5.1)*].

Infusion-Related Reactions

The infusion rate of PERJETA may be slowed or interrupted if the patient develops an infusion-related reaction [see *Warnings and Precautions* (5.3)].

Hypersensitivity Reactions/Anaphylaxis

The infusion should be discontinued immediately if the patient experiences a serious hypersensitivity reaction [see *Warnings and Precautions* (5.4)].

2.3 Preparation for Administration

Administer as an intravenous infusion only. Do not administer as an intravenous push or bolus. Do not mix PERJETA with other drugs.

Preparation

Prepare the solution for infusion, using aseptic technique, as follows:

- Parenteral drug products should be inspected visually for particulates and discoloration prior to administration.
- Withdraw the appropriate volume of PERJETA solution from the vial(s).
- Dilute into a 250 mL 0.9% sodium chloride PVC or non-PVC polyolefin infusion bag.
- Mix diluted solution by gentle inversion. Do not shake.
- Administer immediately once prepared.
- If the diluted infusion solution is not used immediately, it can be stored at 2°C to 8°C for up to 24 hours.
- Dilute with 0.9% Sodium Chloride injection only. Do not use dextrose (5%) solution.

3 DOSAGE FORMS AND STRENGTHS

PERJETA (pertuzumab) 420 mg/14 mL (30 mg/mL) in a single-use vial

4 CONTRAINDICATIONS

PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients.

5 WARNINGS AND PRECAUTIONS

5.1 Left Ventricular Dysfunction

Decreases in LVEF have been reported with drugs that block HER2 activity, including PERJETA. In Study 1, for patients with MBC, PERJETA in combination with trastuzumab and docetaxel was not associated with increases in the incidence of symptomatic left ventricular systolic dysfunction (LVSD) or decreases in LVEF compared with placebo in combination with trastuzumab and docetaxel [see *Clinical Studies* (14.1)]. Left ventricular dysfunction occurred in 4.4% of patients in the PERJETA-treated group and 8.3% of patients in the placebo-treated group. Symptomatic left ventricular systolic dysfunction (congestive heart failure) occurred in 1.0% of patients in the PERJETA-treated group and 1.8% of patients in the placebo-treated group [see *Adverse Reactions* (6.1)]. Patients who have received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of decreased LVEF.

In patients receiving neoadjuvant treatment in Study 2, the incidence of LVSD was higher in the PERJETA-treated groups compared to the trastuzumab- and docetaxel-treated group. An increased incidence of LVEF declines was observed in patients treated with PERJETA in

combination with trastuzumab and docetaxel. In the overall treatment period, LVEF decline > 10% and a drop to less than 50% occurred in 1.9% of patients treated with neoadjuvant trastuzumab and docetaxel as compared to 8.4% of patients treated with neoadjuvant PERJETA in combination with trastuzumab and docetaxel. Symptomatic LVSD occurred in 0.9% of patients treated with neoadjuvant PERJETA in combination with trastuzumab and no patients in the other 3 arms. LVEF recovered to $\geq 50\%$ in all patients.

In patients receiving neoadjuvant PERJETA in Study 3, in the overall treatment period, LVEF decline > 10% and a drop to less than 50% occurred in 6.9% of patients treated with PERJETA plus trastuzumab and FEC followed by PERJETA plus trastuzumab and docetaxel, 16.0% of patients treated with PERJETA plus trastuzumab and docetaxel following FEC, and 10.5% of patients treated with PERJETA in combination with TCH. Symptomatic LVSD occurred in 4.0% of patients treated with PERJETA plus trastuzumab and docetaxel following FEC, 1.3% of patients treated with PERJETA in combination with TCH, and none of the patients treated with PERJETA plus trastuzumab and FEC followed by PERJETA plus trastuzumab and docetaxel. LVEF recovered to $\geq 50\%$ in all but one patient.

PERJETA has not been studied in patients with a pretreatment LVEF value of $\leq 50\%$, a prior history of CHF, decreases in LVEF to < 50% during prior trastuzumab therapy, or conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment or a cumulative prior anthracycline exposure to > 360 mg/m² of doxorubicin or its equivalent.

Assess LVEF prior to initiation of PERJETA and at regular intervals (e.g., every three months in the metastatic setting and every six weeks in the neoadjuvant setting) during treatment to ensure that LVEF is within the institution's normal limits. If LVEF is < 45%, or is 45% to 49% with a 10% or greater absolute decrease below the pretreatment value, withhold PERJETA and trastuzumab and repeat LVEF assessment within approximately 3 weeks. Discontinue PERJETA and trastuzumab if the LVEF has not improved or has declined further, unless the benefits for the individual patient outweigh the risks [*see Dosage and Administration (2.2)*].

5.2 Embryo-Fetal Toxicity

Based on its mechanism of action and findings in animal studies, PERJETA can cause fetal harm when administered to a pregnant woman. PERJETA is a HER2/neu receptor antagonist. Cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported with use of another HER2/neu receptor antagonist (trastuzumab) during pregnancy. In an animal reproduction study, administration of pertuzumab to pregnant cynomolgus monkeys during the period of organogenesis resulted in oligohydramnios, delayed fetal kidney development, and embryo-fetal death at exposures 2.5 to 20 times the exposure in humans at the recommended dose, based on C_{max}.

Verify the pregnancy status of females of reproductive potential prior to the initiation of PERJETA. Advise pregnant women and females of reproductive potential that exposure to PERJETA in combination with trastuzumab during pregnancy or within 7 months prior to conception can result in fetal harm, including embryo-fetal death or birth defects. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of PERJETA in combination with trastuzumab [*see Use in Specific Populations (8.1, 8.3)*].

5.3 Infusion-Related Reactions

PERJETA has been associated with infusion reactions [see *Adverse Reactions (6.1)*]. An infusion reaction was defined in Study 1 as any event described as hypersensitivity, anaphylactic reaction, acute infusion reaction, or cytokine release syndrome occurring during an infusion or on the same day as the infusion. The initial dose of PERJETA was given the day before trastuzumab and docetaxel to allow for the examination of PERJETA-associated reactions. On the first day, when only PERJETA was administered, the overall frequency of infusion reactions was 13.0% in the PERJETA-treated group and 9.8% in the placebo-treated group. Less than 1% were Grade 3 or 4. The most common infusion reactions ($\geq 1.0\%$) were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity, and vomiting.

During the second cycle when all drugs were administered on the same day, the most common infusion reactions in the PERJETA-treated group ($\geq 1.0\%$) were fatigue, dysgeusia, hypersensitivity, myalgia, and vomiting.

In Study 2 and Study 3, PERJETA was administered on the same day as the other study treatment drugs. Infusion reactions were consistent with those observed in Study 1, with a majority of reactions being National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI - CTCAE v3.0) Grade 1 – 2.

Observe patients closely for 60 minutes after the first infusion and for 30 minutes after subsequent infusions of PERJETA. If a significant infusion-related reaction occurs, slow or interrupt the infusion, and administer appropriate medical therapies. Monitor patients carefully until complete resolution of signs and symptoms. Consider permanent discontinuation in patients with severe infusion reactions [see *Dosage and Administration (2.2)*].

5.4 Hypersensitivity Reactions/Anaphylaxis

In Study 1, the overall frequency of hypersensitivity/anaphylaxis reactions was 10.8% in the PERJETA-treated group and 9.1% in the placebo-treated group. The incidence of Grade 3 – 4 hypersensitivity/anaphylaxis reactions was 2.0% in the PERJETA-treated group and 2.5% in the placebo-treated group according to NCI - CTCAE v3.0. Overall, 4 patients in PERJETA-treated group and 2 patients in the placebo-treated group experienced anaphylaxis.

In Study 2 and Study 3, hypersensitivity/anaphylaxis events were consistent with those observed in Study 1. In Study 2, two patients in the PERJETA- and docetaxel-treated group experienced anaphylaxis. In Study 3, the overall frequency of hypersensitivity/anaphylaxis was highest in the PERJETA plus TCH treated group (13.2%), of which 2.6% were NCI-CTCAE (version 3) Grade 3 – 4.

Patients should be observed closely for hypersensitivity reactions. Severe hypersensitivity, including anaphylaxis, has been observed in clinical trials with treatment of PERJETA [see *Clinical Trials Experience (6.1)*]. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use. PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients [see *Contraindications (4)*].

5.5 HER2 Testing

Detection of HER2 protein overexpression is necessary for selection of patients appropriate for PERJETA therapy because these are the only patients studied and for whom benefit has been shown [see *Indications and Usage (1)* and *Clinical Studies (14)*]. Patients with breast cancer were required to have evidence of HER2 overexpression defined as 3+ IHC or FISH amplification ratio ≥ 2.0 in the clinical studies. Only limited data were available for patients

whose breast cancer was positive by FISH, but did not demonstrate protein overexpression by IHC.

Assessment of HER2 status should be performed by laboratories using FDA-approved tests with demonstrated proficiency in the specific technology being utilized. Improper assay performance, including use of sub-optimally fixed tissue, failure to utilize specified reagents, deviation from specific assay instructions, and failure to include appropriate controls for assay validation, can lead to unreliable results.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the label:

- Left Ventricular Dysfunction [*see Warnings and Precautions (5.1)*]
- Embryo-Fetal Toxicity [*see Warnings and Precautions (5.2)*]
- Infusion-Related Reactions [*see Warnings and Precautions (5.3)*]
- Hypersensitivity Reactions/Anaphylaxis [*see Warnings and Precautions (5.4)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Metastatic Breast Cancer (MBC)

The adverse reactions described in Table 1 were identified in 804 patients with HER2-positive metastatic breast cancer treated in Study 1. Patients were randomized to receive either PERJETA in combination with trastuzumab and docetaxel or placebo in combination with trastuzumab and docetaxel. The median duration of study treatment was 18.1 months for patients in the PERJETA-treated group and 11.8 months for patients in the placebo-treated group. No dose adjustment was permitted for PERJETA or trastuzumab. The rates of adverse events resulting in permanent discontinuation of all study therapy were 6.1% for patients in the PERJETA-treated group and 5.3% for patients in the placebo-treated group. Adverse events led to discontinuation of docetaxel alone in 23.6% of patients in the PERJETA-treated group and 23.2% of patients in the placebo-treated group. Table 1 reports the adverse reactions that occurred in at least 10% of patients in the PERJETA-treated group. The safety profile of PERJETA remained unchanged with an additional 2.75 years of follow-up (median total follow-up of 50 months) in Study 1.

The most common adverse reactions (> 30%) seen with PERJETA in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy. The most common NCI - CTCAE v3.0 Grade 3 – 4 adverse reactions (> 2%) were neutropenia, febrile neutropenia, leukopenia, diarrhea, peripheral neuropathy, anemia, asthenia, and fatigue. An increased incidence of febrile neutropenia was observed for Asian patients in both treatment arms compared with patients of other races and from other geographic regions. Among Asian patients, the incidence of febrile neutropenia was higher in the pertuzumab-treated group (26%) compared with the placebo-treated group (12%).

242
243

**Table 1 Summary of Adverse Reactions Occurring in $\geq 10\%$
of Patients on the PERJETA Treatment Arm in Study 1**

Body System/ Adverse Reactions	PERJETA + trastuzumab + docetaxel n=407 Frequency rate %		Placebo + trastuzumab + docetaxel n=397 Frequency rate %	
	All Grades %	Grades 3 – 4 %	All Grades %	Grades 3 – 4 %
General disorders and administration site conditions				
Fatigue	37.6	2.2	36.8	3.3
Asthenia	26.0	2.5	30.2	1.5
Edema peripheral	23.1	0.5	30.0	0.8
Mucosal inflammation	27.8	1.5	19.9	1.0
Pyrexia	18.7	1.2	17.9	0.5
Skin and subcutaneous tissue disorders				
Alopecia	60.9	0.0	60.5	0.3
Rash	33.7	0.7	24.2	0.8
Nail disorder	22.9	1.2	22.9	0.3
Pruritus	14.0	0.0	10.1	0.0
Dry skin	10.6	0.0	4.3	0.0
Gastrointestinal disorders				
Diarrhea	66.8	7.9	46.3	5.0
Nausea	42.3	1.2	41.6	0.5
Vomiting	24.1	1.5	23.9	1.5
Constipation	15.0	0.0	24.9	1.0
Stomatitis	18.9	0.5	15.4	0.3
Blood and lymphatic system disorders				
Neutropenia	52.8	48.9	49.6	45.8
Anemia	23.1	2.5	18.9	3.5
Leukopenia	18.2	12.3	20.4	14.6
Febrile neutropenia*	13.8	13.0	7.6	7.3
Nervous system disorders				
Neuropathy peripheral	32.4	3.2	33.8	2.0
Headache	20.9	1.2	16.9	0.5

Dysgeusia	18.4	0.0	15.6	0.0
Dizziness	12.5	0.5	12.1	0.0
Musculoskeletal and connective tissue disorders				
Myalgia	22.9	1.0	23.9	0.8
Arthralgia	15.5	0.2	16.1	0.8
Infections and infestations				
Upper respiratory tract infection	16.7	0.7	13.4	0.0
Nasopharyngitis	11.8	0.0	12.8	0.3
Respiratory, thoracic, and mediastinal disorders				
Dyspnea	14.0	1.0	15.6	2.0
Metabolism and nutrition disorders				
Decreased appetite	29.2	1.7	26.4	1.5
Eye disorders				
Lacrimation increased	14.0	0.0	13.9	0.0
Psychiatric disorders				
Insomnia	13.3	0.0	13.4	0.0

* In this table this denotes an adverse reaction that has been reported in association with a fatal outcome

The following clinically relevant adverse reactions were reported in < 10% of patients in the PERJETA-treated group in Study 1:

Skin and subcutaneous tissue disorders: Paronychia (7.1% in the PERJETA-treated group vs. 3.5% in the placebo-treated group)

Respiratory, thoracic and mediastinal disorders: Pleural effusion (5.2% in the PERJETA-treated group vs. 5.8% in the placebo-treated group)

Cardiac disorders: Left ventricular dysfunction (4.4% in the PERJETA-treated group vs. 8.3% in the placebo-treated group) including symptomatic left ventricular systolic dysfunction (CHF) (1.0% in the PERJETA-treated group vs. 1.8% in the placebo-treated group)

Immune system disorders: Hypersensitivity (10.1% in the PERJETA-treated group vs. 8.6% in placebo-treated group)

Adverse Reactions Reported in Patients Receiving PERJETA and Trastuzumab after Discontinuation of Docetaxel

In Study 1, adverse reactions were reported less frequently after discontinuation of docetaxel treatment. All adverse reactions in the PERJETA and trastuzumab treatment group occurred in < 10% of patients with the exception of diarrhea (19.1%), upper respiratory tract infection (12.8%), rash (11.7%), headache (11.4%), and fatigue (11.1%).

Neoadjuvant Treatment of Breast Cancer (Study 2)

In Study 2, the most common adverse reactions seen with PERJETA in combination with trastuzumab and docetaxel administered for 4 cycles were similar to those seen in the PERJETA-treated group in Study 1. The most common adverse reactions (> 30%) were alopecia,

neutropenia, diarrhea, and nausea. The most common NCI – CTCAE v3.0 Grade 3 – 4 adverse reactions (> 2%) were neutropenia, febrile neutropenia, leukopenia, and diarrhea. In this group, one patient permanently discontinued neoadjuvant treatment due to an adverse event. Table 2 reports the adverse reactions that occurred in patients who received neoadjuvant treatment with PERJETA for breast cancer in Study 2.

**Table 2 Summary of Adverse Reactions Occurring in ≥ 10%
in the Neoadjuvant Setting for Patients Receiving PERJETA in Study 2**

Body System/ Adverse Reactions	Trastuzumab + docetaxel n=107 Frequency rate %		PERJETA + trastuzumab + docetaxel n=107 Frequency rate %		PERJETA + trastuzumab n=108 Frequency rate %		PERJETA + docetaxel n=108 Frequency rate %	
	All Grades %	Grades 3 – 4 %	All Grades %	Grades 3 – 4 %	All Grades %	Grades 3 – 4 %	All Grades %	Grades 3 – 4 %
General disorders and administration site conditions								
Fatigue	27.1	0.0	26.2	0.9	12.0	0.0	25.5	1.1
Asthenia	17.8	0.0	20.6	1.9	2.8	0.0	16.0	2.1
Edema peripheral	10.3	0.0	2.8	0.0	0.9	0.0	5.3	0.0
Mucosal inflammation	21.5	0.0	26.2	1.9	2.8	0.0	25.5	0.0
Pyrexia	10.3	0.0	16.8	0.0	8.3	0.0	8.5	0.0
Skin and subcutaneous tissue disorders								
Alopecia	66.4	0.0	65.4	0.0	2.8	0.0	67.0	0.0
Rash	21.5	1.9	26.2	0.9	11.1	0.0	28.7	1.1
Gastrointestinal disorders								
Diarrhea	33.6	3.7	45.8	5.6	27.8	0.0	54.3	4.3
Nausea	36.4	0.0	39.3	0.0	13.9	0.0	36.2	1.1
Vomiting	12.1	0.0	13.1	0.0	4.6	0.0	16.0	2.1
Stomatitis	7.5	0.0	17.8	0.0	4.6	0.0	9.6	0.0
Blood and lymphatic system disorders								
Neutropenia	63.6	58.9	50.5	44.9	0.9	0.9	64.9	57.4
Leukopenia	21.5	11.2	9.3	4.7	0.0	0.0	13.8	8.5
Nervous system disorders								
Headache	11.2	0.0	11.2	0.0	13.9	0.0	12.8	0.0
Dysgeusia	10.3	0.0	15.0	0.0	4.6	0.0	7.4	0.0
Peripheral Sensory Neuropathy	12.1	0.9	8.4	0.9	1.9	0.0	10.6	0.0

Musculoskeletal and connective tissue disorders								
Myalgia	22.4	0.0	22.4	0.0	9.3	0.0	21.3	0.0
Arthralgia	8.4	0.0	10.3	0.0	4.6	0.0	9.6	0.0
Metabolism and nutrition disorders								
Decreased appetite	6.5	0.0	14.0	0.0	1.9	0.0	14.9	0.0
Psychiatric disorders								
Insomnia	11.2	0.0	8.4	0.0	3.7	0.0	8.5	0.0

The following adverse reactions were reported in < 10% of patients receiving neoadjuvant treatment and occurred more frequently in PERJETA-treated groups in Study 2: (Ptz=pertuzumab; T=trastuzumab; D=docetaxel)

Blood and lymphatic system disorders: Anemia (6.5% in the T+D arm, 2.8% in the Ptz+T+D arm, 4.6% in the Ptz+T arm and 8.5% in the Ptz+D arm), Febrile neutropenia (6.5% in the T+D arm, 8.4% in the Ptz+T+D arm, 0.0% in the Ptz+T arm and 7.4% in the Ptz+D arm)

Immune system disorders: Hypersensitivity (1.9% in the T+D arm, 5.6% in the Ptz+T+D arm, 5.6% in the Ptz+T arm and 5.3% in the Ptz+D arm)

Nervous system disorders: Dizziness (3.7% in the T+D arm, 2.8% in the Ptz+T+D arm, 5.6% in the Ptz+T arm and 3.2% in the Ptz+D arm)

Infections and infestations: Upper respiratory tract infection (2.8% in the T+D arm, 4.7% in the Ptz+T+D arm, 1.9% in the Ptz+T arm and 7.4% in the Ptz+D arm)

Respiratory, thoracic and mediastinal disorders: Dyspnea (3.7% in the T+D arm, 4.7% in the Ptz+T+D arm, 2.8% in the Ptz+T arm and 2.1% in the Ptz+D arm)

Cardiac disorders: Left ventricular dysfunction (0.9% in the T+D arm, 2.8% in the Ptz+T+D arm, 0.0% in the Ptz+T arm, and 1.1% in the Ptz+D arm) including symptomatic left ventricular dysfunction (CHF) (0.9% in the Ptz+T arm and 0.0% in the T+D arm, Ptz+T+D arm, and Ptz+D arm)

Eye disorders: Lacrimation increased (1.9% in the T+D arm, 3.7% in the Ptz+T+D arm, 0.9% in the Ptz+T arm, and 4.3% in the Ptz+D arm)

Neoadjuvant Treatment of Breast Cancer (Study 3)

In Study 3, when PERJETA was administered in combination with trastuzumab and docetaxel for 3 cycles following 3 cycles of FEC, the most common adverse reactions (> 30%) were diarrhea, nausea, alopecia, neutropenia, vomiting, and fatigue. The most common NCI-CTCAE (version 3) Grade 3 – 4 adverse reactions (> 2%) were neutropenia, leukopenia, febrile neutropenia, diarrhea, left ventricular dysfunction, anemia, dyspnea, nausea, and vomiting.

Similarly, when PERJETA was administered in combination with docetaxel, carboplatin, and trastuzumab (TCH) for 6 cycles, the most common adverse reactions (> 30%) were diarrhea, alopecia, neutropenia, nausea, fatigue, vomiting, anemia, and thrombocytopenia. The most common NCI-CTCAE (version 3) Grade 3 – 4 adverse reactions (> 2%) were neutropenia, febrile neutropenia, anemia, leukopenia, diarrhea, thrombocytopenia, vomiting, fatigue, ALT increased, hypokalemia, and hypersensitivity.

The rates of adverse events resulting in permanent discontinuation of any component of neoadjuvant treatment were 6.7% for patients receiving PERJETA in combination with trastuzumab and docetaxel following FEC and 7.9% for patients receiving PERJETA in combination with TCH. Table 3 reports the adverse reactions that occurred in patients who received neoadjuvant treatment with PERJETA for breast cancer in Study 3.

Table 3 Summary of Adverse Reactions Occurring in $\geq 10\%$ of Patients Receiving Neoadjuvant Treatment with PERJETA in Study 3

Body System/Adverse Reactions	PERJETA + trastuzumab + FEC followed by PERJETA + trastuzumab + docetaxel n=72 Frequency rate %		PERJETA + trastuzumab + docetaxel following FEC n=75 Frequency rate %		PERJETA + TCH n=76 Frequency rate %	
	All Grades %	Grades 3 – 4 %	All Grades %	Grades 3 – 4 %	All Grades %	Grades 3 – 4 %
General disorders and administration site conditions						
Fatigue	36.1	0.0	36.0	0.0	42.1	3.9
Asthenia	9.7	0.0	14.7	1.3	13.2	1.3
Edema peripheral	11.1	0.0	4.0	0.0	9.2	0.0
Mucosal inflammation	23.6	0.0	20.0	0.0	17.1	1.3
Pyrexia	16.7	0.0	9.3	0.0	15.8	0.0
Skin and subcutaneous tissue disorders						
Alopecia	48.6	0.0	52.0	0.0	55.3	0.0
Rash	19.4	0.0	10.7	0.0	21.1	1.3
Dry skin	5.6	0.0	9.3	0.0	10.5	0.0
Palmar-Plantar Erythrodysesthesia Syndrome	6.9	0.0	10.7	0.0	7.9	0.0
Gastrointestinal disorders						
Diarrhea	61.1	4.2	61.3	5.3	72.4	11.8
Dyspepsia	25.0	1.4	8	0.0	22.4	0.0
Nausea	52.8	0.0	53.3	2.7	44.7	0.0
Vomiting	40.3	0.0	36.0	2.7	39.5	5.3

Constipation	18.1	0.0	22.7	0.0	15.8	0.0
Stomatitis	13.9	0.0	17.3	0.0	11.8	0.0
Blood and lymphatic system disorders						
Neutropenia	51.4	47.2	46.7	42.7	48.7	46.1
Anemia	19.4	1.4	9.3	4.0	38.2	17.1
Leukopenia	22.2	19.4	16.0	12.0	17.1	11.8
Febrile neutropenia	18.1	18.1	9.3	9.3	17.1	17.1
Thrombocytopenia	6.9	0.0	1.3	0.0	30.3	11.8
Immune system disorders						
Hypersensitivity	9.7	2.8	1.3	0.0	11.8	2.6
Nervous system disorders						
Neuropathy peripheral	5.6	0.0	1.3	0.0	10.5	0.0
Headache	22.2	0.0	14.7	0.0	17.1	0.0
Dysgeusia	11.1	0.0	13.3	0.0	21.1	0.0
Dizziness	8.3	0.0	8.0	1.3	15.8	0.0
Musculoskeletal and connective tissue disorders						
Myalgia	16.7	0.0	10.7	1.3	10.5	0.0
Arthralgia	11.1	0.0	12.0	0.0	6.6	0.0
Respiratory, thoracic, and mediastinal disorders						
Cough	9.7	0.0	5.3	0.0	11.8	0.0
Dyspnea	12.5	0.0	8.0	2.7	10.5	1.3
Epistaxis	11.1	0.0	10.7	0.0	15.8	1.3
Oropharyngeal pain	8.3	0.0	6.7	0.0	11.8	0.0
Metabolism and nutrition disorders						
Decreased appetite	20.8	0.0	10.7	0.0	21.1	0.0
Eye disorders						
Lacrimation increased	12.5	0.0	5.3	0.0	7.9	0.0
Psychiatric disorders						
Insomnia	11.1	0.0	13.3	0.0	21.1	0.0
Investigations						
ALT increased	6.9	0.0	2.7	0.0	10.5	3.9

316 FEC=5-fluorouracil, epirubicin, cyclophosphamide, TCH=docetaxel, carboplatin, trastuzumab

The following selected adverse reactions were reported in < 10% of patients receiving neoadjuvant treatment in Study 3: (Ptz=pertuzumab; T=trastuzumab; D=docetaxel; FEC= fluorouracil, epirubicin, and cyclophosphamide; TCH=docetaxel, carboplatin, and trastuzumab)

Skin and subcutaneous tissue disorders: Nail disorder (9.7% in the Ptz+T+FEC/Ptz+T+D arm, 6.7% in the FEC/Ptz+T+D arm, and 9.2% in the Ptz+TCH arm), Paronychia (0% in the Ptz+T+FEC/Ptz+T+D and 1.3% in both the FEC/Ptz+T+D and Ptz+TCH arms), Pruritus (2.8% in the Ptz+T+FEC/Ptz+T+D arm, 4.0% in the FEC/Ptz+T+D arm, and 3.9% in the Ptz+TCH arm)

Infections and infestations: Upper respiratory tract infection (8.3% in the Ptz+T+FEC/Ptz+T+D arm, 4.0% in the FEC/Ptz+T+D arm, and 2.6% in the Ptz+TCH arm), Nasopharyngitis (6.9% in the Ptz+T+FEC/Ptz+T+D arm, 6.7% in the FEC/Ptz+T+D arm, and 7.9% in the Ptz+TCH arm)

Respiratory, thoracic, and mediastinal disorders: Pleural effusion (1.4% in the Ptz+T+FEC/Ptz+T+D arm and 0% in the FEC/Ptz+T+D and Ptz+TCH arm)

Cardiac disorders: Left ventricular dysfunction (5.6% in the Ptz+T+FEC/Ptz+T+D arm, 4.0% in the FEC/Ptz+T+D arm, and 2.6% in the Ptz+TCH arm) including symptomatic left ventricular systolic dysfunction (CHF) (2.7% in the FEC/Ptz+T+D arm and 0% in the Ptz+T+FEC/Ptz+T+D and Ptz+TCH arms)

6.2 Immunogenicity

As with all therapeutic proteins, there is the potential for an immune response to PERJETA.

Patients in Study 1 were tested at multiple time-points for antibodies to PERJETA. Approximately 2.8% (11/386) of patients in the PERJETA-treated group and 6.2% (23/372) of patients in the placebo-treated group tested positive for anti-PERJETA antibodies. Of these 34 patients, none experienced anaphylactic/hypersensitivity reactions that were clearly related to the anti-therapeutic antibodies (ATA). The presence of pertuzumab in patient serum at the levels expected at the time of ATA sampling can interfere with the ability of this assay to detect anti-pertuzumab antibodies. In addition, the assay may be detecting antibodies to trastuzumab. As a result, data may not accurately reflect the true incidence of anti-pertuzumab antibody development.

Immunogenicity data are highly dependent on the sensitivity and specificity of the test methods used. Additionally, the observed incidence of a positive result in a test method may be influenced by several factors, including sample handling, timing of sample collection, drug interference, concomitant medication, and the underlying disease. For these reasons, comparison of the incidence of antibodies to PERJETA with the incidence of antibodies to other products may be misleading.

7 DRUG INTERACTIONS

No drug-drug interactions were observed between pertuzumab and trastuzumab, or between pertuzumab and docetaxel.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry and Pharmacovigilance Program

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to PERJETA during pregnancy. Encourage women who receive PERJETA in combination with

trastuzumab during pregnancy or within 7 months prior to conception, to enroll in the MoTHER Pregnancy Registry by contacting 1-800-690-6720 or visiting <http://www.motherpregnancyregistry.com/>.

In addition, there is a pregnancy pharmacovigilance program for PERJETA. If PERJETA is administered during pregnancy, or if a patient becomes pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with trastuzumab, health care providers and patients should immediately report PERJETA exposure to Genentech at 1-888-835-2555.

Risk Summary

Based on its mechanism of action and findings in animal studies, PERJETA can cause fetal harm when administered to a pregnant woman. There are no available data on the use of PERJETA in pregnant women. However, in post-marketing reports, use of another HER2/neu receptor antagonist (trastuzumab) during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. In an animal reproduction study, administration of pertuzumab to pregnant cynomolgus monkeys during the period of organogenesis resulted in oligohydramnios, delayed fetal kidney development, and embryo-fetal deaths at clinically relevant exposures that were 2.5 to 20-fold greater than exposures in humans receiving the recommended dose, based on C_{max} [see Data]. Apprise the patient of the potential risks to a fetus. There are clinical considerations if PERJETA in combination with trastuzumab is used during pregnancy or within 7 months prior to conception [see Clinical Considerations].

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Monitor women who received PERJETA in combination with trastuzumab during pregnancy or within 7 months prior to conception for oligohydramnios. If oligohydramnios occurs, perform fetal testing that is appropriate for gestational age and consistent with community standards of care.

Data

Animal Data

Pregnant cynomolgus monkeys were treated on Gestational Day (GD)19 with loading doses of 30 to 150 mg/kg pertuzumab, followed by bi-weekly doses of 10 to 100 mg/kg. These dose levels resulted in clinically relevant exposures of 2.5 to 20-fold greater than exposures in humans receiving the recommended dose, based on C_{max} . Intravenous administration of pertuzumab from GD19 through GD50 (period of organogenesis) was embryotoxic, with dose-dependent increases in embryo-fetal death between GD25 to GD70. The incidences of embryo-fetal loss were 33, 50, and 85% for dams treated with bi-weekly pertuzumab doses of 10, 30, and 100 mg/kg, respectively (2.5 to 20-fold greater than the recommended human dose, based on C_{max}). At Caesarean section on GD100, oligohydramnios, decreased relative lung and kidney

weights, and microscopic evidence of renal hypoplasia consistent with delayed renal development were identified in all pertuzumab dose groups. Pertuzumab exposure was reported in offspring from all treated groups, at levels of 29% to 40% of maternal serum levels at GD100.

8.2 Lactation

Risk Summary

There is no information regarding the presence of pertuzumab in human milk, the effects on the breastfed infant or the effects on milk production. Published data suggest that human IgG is present in human milk but does not enter the neonatal and infant circulation in substantial amounts. Consider the developmental and health benefits of breast feeding along with the mother's clinical need for PERJETA treatment and any potential adverse effects on the breastfed child from PERJETA or from the underlying maternal condition. This consideration should also take into account the elimination half-life of pertuzumab and the trastuzumab wash out period of 7 months.

8.3 Females and Males of Reproductive Potential

Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to the initiation of PERJETA.

Contraception

Females

Based on the mechanism of action and animal data, PERJETA can cause embryo-fetal harm when administered during pregnancy. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of PERJETA in combination with trastuzumab [see *Use in Specific Populations (8.1)*].

8.4 Pediatric Use

The safety and effectiveness of PERJETA have not been established in pediatric patients.

8.5 Geriatric Use

Of 402 patients who received PERJETA in Study 1, 60 patients (15%) were ≥ 65 years of age and 5 patients (1%) were ≥ 75 years of age. No overall differences in efficacy and safety of PERJETA were observed between these patients and younger patients.

Based on a population pharmacokinetic analysis, no significant difference was observed in the pharmacokinetics of pertuzumab between patients < 65 years ($n=306$) and patients ≥ 65 years ($n=175$).

8.6 Renal Impairment

Dose adjustments of PERJETA are not needed in patients with mild (creatinine clearance [CLcr] 60 to 90 mL/min) or moderate (CLcr 30 to 60 mL/min) renal impairment. No dose adjustment can be recommended for patients with severe renal impairment (CLcr less than 30 mL/min) because of the limited pharmacokinetic data available [see *Clinical Pharmacology (12.3)*].

8.7 Hepatic Impairment

No clinical studies have been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of pertuzumab.

10 OVERDOSAGE

No drug overdoses have been reported with PERJETA to date.

11 DESCRIPTION

Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). Pertuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture that may contain the antibiotic, gentamicin. Gentamicin is not detectable in the final product. Pertuzumab has an approximate molecular weight of 148 kDa.

PERJETA is a sterile, clear to slightly opalescent, colorless to pale brown liquid for intravenous infusion. Each single use vial contains 420 mg of pertuzumab at a concentration of 30 mg/mL in 20 mM L-histidine acetate (pH 6.0), 120 mM sucrose and 0.02% polysorbate 20.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through two major signal pathways, mitogen-activated protein (MAP) kinase, and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis, respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated cytotoxicity (ADCC).

While pertuzumab alone inhibited the proliferation of human tumor cells, the combination of pertuzumab and trastuzumab augmented anti-tumor activity in HER2-overexpressing xenograft models.

12.3 Pharmacokinetics

Pertuzumab demonstrated linear pharmacokinetics at a dose range of 2 – 25 mg/kg. Based on a population PK analysis that included 481 patients, the median clearance (CL) of pertuzumab was 0.24 L/day and the median half-life was 18 days. With an initial dose of 840 mg followed by a maintenance dose of 420 mg every three weeks thereafter, the steady-state concentration of pertuzumab was reached after the first maintenance dose.

The population PK analysis suggested no PK differences based on age, gender, ethnicity (Japanese vs. non-Japanese), or disease status (neoadjuvant versus metastatic setting). Baseline serum albumin level and lean body weight as covariates only exerted a minor influence on PK parameters. Therefore, no dose adjustments based on body weight or baseline albumin level are needed.

No drug-drug interactions were observed between pertuzumab and trastuzumab, or between pertuzumab and docetaxel in a sub-study of 37 patients in Study 1.

No dedicated renal impairment trial for PERJETA has been conducted. Based on the results of the population pharmacokinetic analysis, pertuzumab exposure in patients with mild (CLcr 60 to 90 mL/min, n=200) and moderate renal impairment (CLcr 30 to 60 mL/min, n=71) were similar to those in patients with normal renal function (CLcr greater than 90 mL/min, n=200). No relationship between CLcr and pertuzumab exposure was observed over the range of observed CLcr (27 to 244 mL/min).

12.6 Cardiac Electrophysiology

The effect of pertuzumab with an initial dose of 840 mg followed by a maintenance dose of 420 mg every three weeks on QTc interval was evaluated in a subgroup of 20 patients with HER2-positive breast cancer in Study 1. No large changes in the mean QT interval (i.e., greater than 20 ms) from placebo based on Fridericia correction method were detected in the trial. A small increase in the mean QTc interval (i.e., less than 10 ms) cannot be excluded because of the limitations of the trial design.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of pertuzumab.

Studies have not been performed to evaluate the mutagenic potential of pertuzumab.

No specific fertility studies in animals have been performed to evaluate the effect of pertuzumab. No adverse effects on male and female reproductive organs were observed in repeat-dose toxicity studies of up to six months duration in cynomolgus monkeys.

14 CLINICAL STUDIES

14.1 Metastatic Breast Cancer

Study 1 was a multicenter, double-blind, placebo-controlled trial of 808 patients with HER2-positive metastatic breast cancer. HER2 overexpression was defined as a score of 3+ IHC or FISH amplification ratio of 2.0 or greater as determined by a central laboratory. Patients were randomly allocated 1:1 to receive placebo plus trastuzumab and docetaxel or PERJETA plus trastuzumab and docetaxel. Randomization was stratified by prior treatment (prior or no prior adjuvant/neoadjuvant anti-HER2 therapy or chemotherapy) and geographic region (Europe, North America, South America, and Asia). Patients with prior adjuvant or neoadjuvant therapy were required to have a disease-free interval of greater than 12 months before trial enrollment.

PERJETA was given intravenously at an initial dose of 840 mg, followed by 420 mg every 3 weeks thereafter. Trastuzumab was given intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks thereafter. Patients were treated with PERJETA and trastuzumab until progression of disease, withdrawal of consent, or unacceptable toxicity. Docetaxel was given as an initial dose of 75 mg/m² by intravenous infusion every 3 weeks for at least 6 cycles. The docetaxel dose could be escalated to 100 mg/m² at the investigator's discretion if the initial dose was well tolerated. At the time of the primary analysis, the mean number of cycles of study treatment administered was 16.2 in the placebo-treated group and 19.9 in the PERJETA-treated group.

The primary endpoint of Study 1 was progression-free survival (PFS) as assessed by an independent review facility (IRF). PFS was defined as the time from the date of randomization to the date of disease progression or death (from any cause) if the death occurred within 18 weeks of the last tumor assessment. Additional endpoints included overall survival (OS), PFS (investigator-assessed), objective response rate (ORR), and duration of response.

Patient demographic and baseline characteristics were balanced between the treatment arms. The median age was 54 (range 22 to 89 years), 59% were White, 32% were Asian, and 4% were Black. All were women with the exception of 2 patients. Seventeen percent of patients were enrolled in North America, 14% in South America, 38% in Europe, and 31% in Asia. Tumor prognostic characteristics, including hormone receptor status (positive 48%, negative 50%),

535 presence of visceral disease (78%) and non-visceral disease only (22%) were similar in the study
536 arms. Approximately half of the patients received prior adjuvant or neoadjuvant anti-HER2
537 therapy or chemotherapy (placebo 47%, PERJETA 46%). Among patients with hormone
538 receptor positive tumors, 45% received prior adjuvant hormonal therapy and 11% received
539 hormonal therapy for metastatic disease. Eleven percent of patients received prior adjuvant or
540 neoadjuvant trastuzumab.

541 Study 1 demonstrated a statistically significant improvement in IRF-assessed PFS in the
542 PERJETA-treated group compared with the placebo-treated group [hazard ratio (HR)=0.62 (95%
543 CI: 0.51, 0.75), $p < 0.0001$] and an increase in median PFS of 6.1 months (median PFS of
544 18.5 months in the PERJETA-treated group vs. 12.4 months in the placebo-treated group) (see
545 Figure 1). The results for investigator-assessed PFS were comparable to those observed for IRF-
546 assessed PFS.

547 Consistent results were observed across several patient subgroups including age (< 65 or
548 ≥ 65 years), race, geographic region, prior adjuvant/neoadjuvant anti-HER2 therapy or
549 chemotherapy (yes or no), and prior adjuvant/neoadjuvant trastuzumab (yes or no). In the
550 subgroup of patients with hormone receptor-negative disease ($n=408$), the hazard ratio was 0.55
551 (95% CI: 0.42, 0.72). In the subgroup of patients with hormone receptor-positive disease
552 ($n=388$), the hazard ratio was 0.72 (95% CI: 0.55, 0.95). In the subgroup of patients with disease
553 limited to non-visceral metastasis ($n=178$), the hazard ratio was 0.96 (95% CI: 0.61, 1.52).

554 At the time of the final PFS analysis, 165 patients had died, and more deaths had occurred in the
555 placebo-treated group (23.6%) compared with the PERJETA-treated group (17.2%); OS was not
556 mature and interim OS analysis results did not meet the pre-specified stopping boundary for
557 statistical significance. The final analysis of OS (Table 4, Figure 2) was performed when 389
558 patients had died (221 in the placebo-treated group and 168 in the PERJETA-treated group). A
559 statistically significant OS improvement in favor of the PERJETA-treated group was
560 demonstrated [HR=0.68 (95% CI: 0.56, 0.84), $p=0.0002$] with an increase in median OS of 15.7
561 months (median OS of 56.5 months in the PERJETA-treated group vs. 40.8 months in the
562 placebo-treated group). OS results in patient subgroups were consistent with those observed for
563 IRF-assessed PFS with the exception of the subgroup of patients with disease limited to non-
564 visceral metastasis [HR=1.11 (95% CI: 0.66, 1.85)].

567

Table 4 Summary of Efficacy from Study 1

Parameter	PERJETA + trastuzumab + docetaxel n=402	Placebo + trastuzumab + docetaxel n=406	HR (95% CI)	p-value
Progression-Free Survival (independent review)				
No. of patients with an event	191 (47.5%)	242 (59.6%)	0.62	
Median months	18.5	12.4	(0.51, 0.75)	< 0.0001
Overall Survival* (final analysis)				
No. of patients who died	168 (41.8%)	221 (54.4%)	0.68	
Median months	56.5	40.8	(0.56, 0.84)	0.0002
Objective Response Rate (ORR, independent review)				
No. of patients analyzed				
Objective response (CR + PR)	343	336		
Complete response (CR)	275 (80.2%)	233 (69.3%)		
Partial Response (PR)	19 (5.5%)	14 (4.2%)		
Median Duration of Response (months)	256 (74.6%) 20.2	219 (65.2%) 12.5		
Difference in ORR 95% CI	10.8% (4.2%, 17.5%)			0.0011


568

569

570 * Final analysis of overall survival, cutoff date Feb 2014

571 CI=Confidence Interval


572 **Figure 1 Kaplan-Meier Curve of IRF-Assessed Progression-Free Survival for Study 1**



573

Ptz + T + D = Pertuzumab + Trastuzumab + Docetaxel
Pla + T + D = Placebo + Trastuzumab + Docetaxel

574 **Figure 2 Kaplan-Meier Curve of Overall Survival for Study 1 (Final Analysis)**



575

14.2 Neoadjuvant Treatment of Breast Cancer

Study 2

Study 2 was a multicenter, randomized trial conducted in 417 patients with operable, locally advanced, or inflammatory HER2-positive breast cancer (T2-4d) who were scheduled for neoadjuvant therapy. HER2 overexpression was defined as a score of 3+ IHC or FISH amplification ratio of 2.0 or greater as determined by a central laboratory. Patients were randomly allocated to receive 1 of 4 neoadjuvant regimens prior to surgery as follows: trastuzumab plus docetaxel, PERJETA plus trastuzumab and docetaxel, PERJETA plus trastuzumab, or PERJETA plus docetaxel. Randomization was stratified by breast cancer type (operable, locally advanced, or inflammatory) and estrogen receptor (ER) or progesterone receptor (PgR) positivity.

PERJETA was given intravenously at an initial dose of 840 mg, followed by 420 mg every 3 weeks for 4 cycles. Trastuzumab was given intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for 4 cycles. Docetaxel was given as an initial dose of 75 mg/m² by intravenous infusion every 3 weeks for 4 cycles. The docetaxel dose could be escalated to 100 mg/m² at the investigator's discretion if the initial dose was well tolerated. Following surgery all patients received 3 cycles of 5-fluorouracil (600 mg/m²), epirubicin (90 mg/m²), and cyclophosphamide (600 mg/m²) (FEC) given intravenously every 3 weeks and trastuzumab administered intravenously every 3 weeks to complete 1 year of therapy. After surgery, patients in the PERJETA plus trastuzumab arm received docetaxel every 3 weeks for 4 cycles prior to FEC.

The primary endpoint of the study was pathological complete response (pCR) rate in the breast (ypT0/is). The FDA-preferred definition of pCR is the absence of invasive cancer in the breast and lymph nodes (ypT0/is ypN0).

Demographics were well balanced (median age was 49 – 50 years old, the majority were Caucasian (71%) and all were female. Overall, 7% of patients had inflammatory cancer, 32% had locally advanced cancer, and 61% had operable cancer. Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as ER-positive and/or PgR-positive).

The efficacy results are summarized in Table 5. Statistically significant improvements in pCR rates by both the study and FDA-preferred definitions were observed in patients receiving PERJETA plus trastuzumab and docetaxel compared to patients receiving trastuzumab plus docetaxel. The pCR rates and magnitude of improvement with PERJETA were lower in the subgroup of patients with hormone receptor-positive tumors compared to patients with hormone receptor-negative tumors.

Table 5 Summary of Efficacy from Study 2

Endpoint/Study Population	H+T	Ptz+H+T	Ptz+H	Ptz+T
Overall ITT	N=107	N=107	N=107	N=96
pCR ¹ , n (%)	23 (21.5%)	42 (39.3%)	12 (11.2%)	17 (17.7%)
[95% CI] ²	[14.1, 30.5]	[30.0, 49.2]	[5.9, 18.8]	[10.7, 26.8]
p-value (with Simes correction for CMH test) ³		0.0063 (vs. H+T)	0.0223 (vs. H+T)	0.0018 (vs. Ptz+H+T)

Hormone receptor-positive subgroup	N=50	N=50	N=51 ⁴	N=46
pCR¹, n (%) [95% CI]²	6 (12.0%) [4.5, 24.3]	11 (22.0%) [11.5, 36.0]	1 (2.0%) [0.1, 10.5]	4 (8.7%) [2.4, 20.8]
Hormone receptor-negative subgroup	N=57	N=57	N=55 ⁴	N=50
pCR¹, n (%) [95% CI]²	17 (29.8%) [18.4, 43.4]	31 (54.4%) [40.7, 67.6]	11 (20.0%) [10.4, 33.0]	13 (26.0%) [14.6, 40.3]

T=docetaxel, Ptz=PERJETA, H=trastuzumab

CI=Confidence Interval

¹ ypT0/is ypN0 (absence of invasive cancer in the breast and lymph nodes)

² 95% CI for one sample binomial using Pearson-Clopper method.

³ p-value from Cochran-Mantel-Haenszel (CMH) test, with Simes multiplicity adjustment

⁴ One patient had unknown hormone receptor status. The patient did not achieve a pCR.

Study 3

An additional phase 2 neoadjuvant study was conducted in 225 patients with HER2-positive locally advanced, operable, or inflammatory (T2-4d) breast cancer designed primarily to assess cardiac safety in which all arms included PERJETA. HER2 overexpression was defined as a score of 3+ IHC or FISH amplification ratio of 2.0 or greater as determined by a central laboratory.

Patients were randomly allocated to receive 1 of 3 neoadjuvant regimens prior to surgery as follows: 3 cycles of FEC followed by 3 cycles of docetaxel all in combination with PERJETA and trastuzumab, 3 cycles of FEC alone followed by 3 cycles of docetaxel and trastuzumab in combination with PERJETA, or 6 cycles of docetaxel, carboplatin, and trastuzumab (TCH) in combination with PERJETA. Randomization was stratified by breast cancer type (operable, locally advanced, or inflammatory) and ER and/or PgR positivity.

PERJETA was given by intravenous infusion at an initial dose of 840 mg, followed by 420 mg every 3 weeks. Trastuzumab was given by intravenous infusion at an initial dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks. 5-Fluorouracil (500 mg/m²), epirubicin (100 mg/m²), and cyclophosphamide (600 mg/m²) were given intravenously every 3 weeks for 3 cycles. In the PERJETA plus trastuzumab, docetaxel, and FEC arms, docetaxel was given as an initial dose of 75 mg/m² by intravenous infusion every 3 weeks for 3 cycles with the option to escalate to 100 mg/m² at the investigator's discretion if the initial dose was well tolerated. However, in the PERJETA plus TCH arm, docetaxel was given intravenously at 75 mg/m² (no escalation was permitted) and carboplatin (AUC 6) was given intravenously every 3 weeks for 6 cycles. Following surgery all patients received trastuzumab to complete 1 year of therapy, which was administered intravenously every 3 weeks.

Demographics were well balanced (median age was 49-50 years old, the majority were Caucasian (76%)) and all were female. Overall 6% of patients had inflammatory cancer, 25%

had locally advanced cancer and 69% had operable cancer, with approximately half the patients in each treatment group having ER-positive and/or PgR-positive disease.

The pCR (ypT0/is ypN0) rates were 56.2% (95% CI: 44.1%, 67.8%), 54.7% (95% CI: 42.7%, 66.2%), and 63.6% (95% CI: 51.9%, 74.3%) for patients treated with PERJETA plus trastuzumab and FEC followed by PERJETA plus trastuzumab and docetaxel, PERJETA plus trastuzumab and docetaxel following FEC, or PERJETA plus TCH, respectively. The pCR rates were lower in the subgroups of patients with hormone receptor-positive tumors: 41.0% (95% CI: 25.6%, 57.9%), 45.7% (95% CI: 28.8%, 63.4%), and 47.5% (95% CI: 31.5%, 63.9%) than with hormone receptor-negative tumors: 73.5% (95% CI: 55.6%, 87.1%), 62.5% (95% CI: 45.8%, 77.3%), and 81.1% (95% CI: 64.8%, 92.0%), respectively.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

PERJETA is supplied as a 420 mg/14 mL (30 mg/mL) single-use vial containing preservative-free solution. NDC 50242-145-01.

Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) until time of use.

Keep vial in the outer carton in order to protect from light.

DO NOT FREEZE. DO NOT SHAKE.

17 PATIENT COUNSELING INFORMATION

Left Ventricular Dysfunction

- Advise patients to contact a health care professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness [*see Warnings and Precautions (5.1)*].

Embryo-Fetal Toxicity

- Advise pregnant women and females of reproductive potential that exposure to PERJETA in combination with trastuzumab during pregnancy or within 7 months prior to conception can result in fetal harm. Advise female patients to contact their healthcare provider with a known or suspected pregnancy [*see Use in Specific Populations (8.1)*].
- Advise women who are exposed to PERJETA in combination with trastuzumab during pregnancy or within 7 months prior to conception that there is a pregnancy exposure registry and a pregnancy pharmacovigilance program that monitors pregnancy outcomes. Encourage these patients to enroll in the MoTHER Pregnancy Registry and report their pregnancy to Genentech [*see Use in Specific Populations (8.1)*].
- Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of PERJETA in combination with trastuzumab [*see Use in Specific Populations (8.3)*].

PERJETA[®] (pertuzumab)

Manufactured by:

Genentech, Inc.

A Member of the Roche Group

1 DNA Way

South San Francisco, CA 94080-4990

U.S. License No. 1048

PERJETA is a registered trademark of Genentech, Inc.

©2017 Genentech, Inc.

681